Vimarsana
Biggest News Aggregation in the World

Alyssa Johnsen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alyssa Johnsen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alyssa Johnsen Today - Breaking & Trending Today

Bristol Myers: will present data on schizophrenia - Vimarsana News

Bristol Myers: will present data on schizophrenia

Bristol Myers Squibb will present data at the 2024 Annual Meeting of the American Society of Clinical Psychopharmacology to be held May 28-31, 2024 in Miami, Florida.Research to be presented at the...

Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting - Vimarsana News

Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting

Consistent with short-term studies, KarXT was not associated with clinically meaningful changes in movement disorder scale scores and a low incidence rate of extrapyramidal symptoms was reported over...

New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis - Vimarsana News

New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis

Following four years of continuous Sotyktu treatment, clinical response was maintained in more than seven out of 10 patients for Psoriasis Area and Severity Index 75 in the POETYK PSO long-term...

Bristol Myers: positive results in psoriasis - Vimarsana News

Bristol Myers: positive results in psoriasis

Bristol Myers Squibb today announced new four-year results from the extension of a trial of Sotyktu in adult patients with moderate-to-severe plaque psoriasis. ''The data [...] continue to reinforce...

New Comprehensive Phase 3 Data Show First-in-Class TREMFYA® (guselkumab) Provided Durable Improvements in Measures of Psoriatic Arthritis (PsA) Disease Activity Through Two Years - Vimarsana News

New Comprehensive Phase 3 Data Show First-in-Class TREMFYA® (guselkumab) Provided Durable Improvements in Measures of Psoriatic Arthritis (PsA) Disease Activity Through Two Years

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced comprehensive efficacy and safety data from the DISCOVER–2 trial of...